LEUKEMIA INHIBITORY FACTOR RECEPTORS

Abstract: Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, are disclosed.

Description: TTT E Leukemia Inhibitory Factor Receptors BACKGROUND OF THE TNVENTTON The present invention relates generally to cytokine receptors, and more specifically, to leukemia inhibitory factor receptors. Leukemia inhibitory factor (LIF) is a polypeptide hormone which plays a central role in the regulation of diverse adult and embryonic systems. LIF acts on a variety of cell types and has multiple biological activities. The diversity in biological activity is reflected in the various synonyms of LIF, which include hepatocyte stimulating factor in (HSF IE); Baumann and Wong, /. Immunol. 143:1163, 1989); cholinergic nerve differentiation factor (CNDF; Yamamori et al., Science 246:1412, 1990); melanoma- derived lipoprotein lipase inhibitor (MLPLI; Mori et al., Biochem. Biophys Res. Comm. 160:1085, 1989); human interleukin for DA cells (HILDA; Moreau et al., Nature 336:690, 1988); differentiation factor (D-factor, Tomida et al., J. Biol. Chem. 259:10978, 1984); differentiation inhibitory factor (DIF; Abe et al., J. Biol. Chem. 264:8941, 1989); differentiation inhibitory activity (DIA; Smith and Hooper, Devel. Biol. 121:1, 1987); and differentiation retarding factor (DRF; Koopman and Cotton, Exp. Cell. Res. 154:233, 1984). The diversity of biological activity ascribed to LIF, whether differentiation inhibition or stimulation, proliferation or functional activitation, is mediated by specific plasma membrane receptors which bind LEF. Despite the wide range of biological activities mediated by LIF, it is believed that LIF receptors (LIF-R) are highly conserved in a variety of species and expressed on a large variety of cells, since the ligand is highly conserved between species (Gough et al., Proc. Natl. Acad. Sci. USA 55:2623, 1988; Yamamori et al., Science 246: 1412, 1990). LIF receptors have been identified by ligand affinity cross-linking techniques on various cell lines, including monocyte-macrophages (Hilton, et al., Proc. Natl. Acad. Sci. USA 85:5971, 1988), and also on some non-hematopoietic cells including osteoblasts, placental trophoblasts, and liver parenchymal cells (Metcalf et al., Blood 76:50, 1990). Such studies indicate that LIF-R has a molecular weight of 90 kDa (Jacques et al., 5th Symposium sur les Marqueurs de rinflammation, Lyon 25-27 September 1990, Abstract No. 37, page 122 (bioMerieux sa, Lyon, France)). Characterization of LIF receptors by Scatchard analysis of binding isotherms has demonstrated that specific cell surface receptor molecules from a variety of target cells have approximately the same affinity for LIF (40-100 pM) and are present in low numbers (150 to 2,500 receptors per cell) on all cells types tested. In order to study the structural and biological characteristics of LIF-R and the role played by LIF-R in the responses of various cell populations to LIF stimulation, or to use LIF-R effectively in therapy, diagnosis, or assay, homogeneous compositions are needed. Such compositions are theoretically available via purification of receptors expressed by cultured cells, or by cloning and expression of genes encoding the receptors. Prior to the present invention, however, several obstacles prevented these goals from being achieved. First, although some cell lines have been identified which express LIF-R, such cell lines express LIF-R only in very low numbers (150 to 2,500 receptors/cell), which has impeded efforts to purify receptors in amounts sufficient for obtaining amino acid sequence information or generating monoclonal antibodies. The low numbers of receptors has also precluded any practical translation assay-based method of cloning. Second, even if LIF-R protein compositions of sufficient purity could be obtained to permit N-terminal protein sequencing, the degeneracy of the genetic code may not permit one to define a suitable probe without considerable additional experimentation. Many iterative attempts may be required to define a probe having the requisite specificity to identify a hybridizing sequence in a cDNA library. Although direct expression cloning techniques avoid the need for repetitive screening using different probes of unknown specificity and have been useful in cloning other receptors (e.g., E -1R), they have not been shown to be sufficiently sensitive to identify LIF-R clones from cDNA libraries derived from cells expressing low numbers of LIF-R. Thus, efforts to purify the LIF-R or to clone or express genes encoding LIF-R have been impeded by lack of purified receptor or a suitable source of receptor mRNA. SUMMARY OF THE INVENTION The present invention provides isolated LIF-R and isolated DNA sequences encoding LIF-R, in particular, human LIF-R, or analogs thereof. Preferably, such DNA sequences are selected from the group consisting of (a) cDNA clones having a nucleotide sequence derived from the coding region of a native LIF-R gene such as human clone 65 (SEQ ID NO:l) and murine clone 3 (SEQ ID NO:3); (b) DNA sequences capable of hybridization to the cDNA clones of (a) under moderately stringent conditions and which encode biologically active LIF-R molecules; and (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active LIF-R molecules. The present invention also provides recombinant expression vectors comprising the DNA sequences defined above, recombinant LIF-R molecules produced using the recombinant expression vectors, and processes for producing the recombinant LIF-R molecules utilizing the expression vectors. The present invention also provides substantially homogeneous protein compositions comprising LIF-R. LIF-R proteins have the sequence of amino acids shown, for example, in SEQ ID NO:2 and SEQ ID NO:4 The present invention also provides compositions for use in therapy, diagnosis, assay of LIF-R, or in raising antibodies to LIF-R, comprising effective quantities of soluble native or recombinant receptor proteins prepared according to the foregoing processes. These and other aspects of the present invention will become evident upon reference to the following detailed description. PETAΪLEP PESCRIPTION Of TffE INVENTION Definitions "Leukemia inhibitory factor receptor" and "LIF-R" refer to proteins which are present on the surface of various hematopoietic cells including monocyte-macrophages and megakaryocytes, and on non-hematopoietic cells, including osteoblasts, placental trophoblasts, and liver parenchymal cells, and which are capable of binding leukemia inhibitory factor (LIF) molecules and, in their native configuration as mammalian plasma membrane proteins, play a role in transducing the signal provided by LIF to a cell. The mature full-length human LIF-R has been previously described as a protein having a molecular weight of approximately 90 kDa; however, the molecular weight of the human LIF-R protein disclosed herein, and shown in SEQ ID NO:2, is about 190,000 kDa. As used herein, the above terms include analogs or subunits of native LIF-R proteins with LIF-binding or signal transducing activity. Specifically included are truncated, soluble or fusion forms of LIF-R protein as defined below. In the absence of any species designation, LIF-R refers generically to mammalian LIF-R, which includes, but is not limited to, human, murine, and bovine LIF-R. Similarly, in the absence of any specific designation for deletion mutants, the term LIF-R means all forms of LIF-R, including mutants and analogs which possess LIF-R biological activity. "Soluble LIF-R" or "sLIF-R" as used in the context of the present invention refer to proteins, or substantially equivalent analogs, which are substantially similar to all or part of the extracellular region of a native LIF-R, and are secreted by the cell but retain the ability to bind LIF or inhibit LIF signal transduction activity via cell surface bound LIF-R proteins. Soluble LIF-R proteins may also include part of the transmembrane region or part of the cytoplasmic domain or other sequences, provided that the soluble LIF-R protein is capable of being secreted from the cell. Inhibition of LIF signal transduction activity can be determined using primary cells or cells lines which express an endogenous LIF-R and which are biologically responsive to LIF or which, when transfected with recombinant LIF-R DNAs, are biologically responsive to LIF. The cells are then contacted with LIF and the resulting metabolic effects examined. If an effect results which is attributable to the action of the ligand, then the recombinant receptor has signal transduction activity. Exemplary procedures for determining whether a polypeptide has signal transduction activity are disclosed by Idzerda et al., /. Exp. Med. 171:861 (1990); Curtis et al., Proc. Natl. Acad. Sci. USA 86:3045 (1989); Prywes et al., EMBO J.5:2179 (1986) and Chou et al., /. Biol. Chem.262:1842 (1987). The term "isolated" or "purified", as used in the context of this specification to define the purity of LIF-R protein or protein compositions, means that the protein or protein composition is substantially free of other proteins of natural or endogenous origin and contains less than about 1% by mass of protein contaminants residual of production processes. Such compositions, however, can contain other proteins added as stabilizers, carriers, excipients or co-therapeutics. LIF-R is "isolated" if it is detectable as a single protein band in a polyaαylamide gel by silver staining. The term "substantially similar," when used to define either amino acid or nucleic acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which is to retain biological activity of the LIF-R protein as may be determined, for example, in an LIF-R binding assays, such as is described in Example 1 below. Alternatively, nucleic acid subunits and analogs are "substantially similar" to the specific DNA sequences disclosed herein if: (a) the DNA sequence is derived from the coding region of LIF-R clone 65; (b) the DNA sequence is capable of hybridization to DNA sequences of (a) under moderately stringent conditions (50°C, 2x SSC) and which encode biologically active LIF-R molecules; or DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b) and which encode biologically active LIF-R molecules. "Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammahan) expression systems. "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Protein expressed in most bacterial cultures, e.g., E. coli, will be free of glycan; protein expressed in yeast may have a glycosylation pattern different from that expressed in mammalian cells. "Biologically active," as used throughout the specification as a characteristic of LIF-R, means either that a particular molecule shares sufficient amino acid sequence similarity with LIF-R clone 65 to be capable of binding detectable quantities of LIF, preferably at least 0.01 nmoles LIF per nanomole LIF-R, or, in the alternative, shares sufficient amino acid sequence similarity to be capable of transmitting an LIF stimulus to a cell, for example, as a component of a hybrid receptor construct. More preferably, biologically active LIF-R within the scope of the present invention is capable of binding greater than 0.1 nanomoles LIF per nanomole receptor, and most preferably, greater than 0.5 nanomoles LEF per nanomole receptor. "DNA sequence" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. However, it will be evident that genomic DNA containing the relevant sequences could also be used. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions. "Nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. DNA sequences encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit. "Recombinant expression vector" refers to a plasmid comprising a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences. Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product "Recombinant microbial expression system" means a substantially homogeneous monoculture of suitable host microorganisms, for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed. Isolation of cDNAs Encoding LIF-R A human DNA sequence encoding human LIF-R was isolated from a cDNA library prepared using standard methods by reverse transcription of polyadenylated RNA isolated from human placental cells. Transfectants expressing biologically active LIF-R were initially identified using a modified slide autoradiographic technique, substantially as described by Gearing et al., EMBO J. 5:3667, 1989. Briefly, COS-7 cells were transfected with miniprep DNA in pDC303 from pools of cDNA clones directly on glass slides and cultured for 2-3 days to permit transient expression of LIF-R. The slides containing the transfected cells were then incubated with medium containing 125[-LIF, washed to remove unbound labeled LIF, fixed with glutaraldehyde, and dipped in liquid photographic emulsion and exposed in the dark. After developing the slides, they were individually examined with a microscope and positive cells expressing LIF-R were identified by the presence of autoradiographic silver grains against a light background. Using this approach, approximately 240,000 cDNAs were screened in pools of approximately 2,400 cDNAs using the slide autoradiographic method until assay of one transfectant pool showed multiple cells clearly positive for LIF binding. This pool was then partitioned into pools of 600 and again screened by slide autoradiography and a positive pool was identified. This pool was further partitioned into pools of 60 and screened by plate binding assays analyzed by quantitation of bound 125l-LIF. The cells were scraped off and counted to determine which pool of 60 was positive. Individual colonies from this pool of 60 were screened until a single clone (clone 65) was identified which directed synthesis of a surface protein with detectable LIF binding activity. This clone was isolated, and its insert is sequenced to determine the sequence of the human LIF-R cDNA clone 65. The cloning vector pDC303 which contains the human LIF-R cDNA clone 65 was deposited with the American Type Culture Collection, Rockville, MD, USA (ATCC) on December 11, 1990, under the name pHLIFR-65 (ATCC Accession No. 68491). The deposit was made under the conditions of the Budapest Treaty. A probe may be constructed from the human sequence and used to screen various other mammalian cDNA libraries. cDNA clones which hybridized to the human probe are then isolated and sequenced. Like most mammalian genes, mammalian LIF-R is presumably encoded by multi-exon genes. Alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein, are considered to be within the scope of the present invention. Analysis of cDNA Clones Encoding LIF-R The DNA sequence and translated amino acid sequence of the cDNA clones encoding LIF-R are shown in the Sequence Listing. SEQ ID NO:l and SEQ ID NO:2 show the nucleotide sequence and predicted amino acid sequence of human LIF-R clone 65. This particular clone is a 5 * fragment, lacking the the 3' end of the coding region. The coding region spans from nucleotides 179-3182. The partial amino acid sequence of the mature peptide encoded by this nucleotide sequence is defined by amino acids 1-957. The predicted signal peptide is defined by amino acids -44 through -1. SEQ ID NO:3 and SEQ ID NO:4 show the nucleotide sequence and predicted amino acid sequence of murine LIF-R clone 3. This particular clone is a naturally occurring soluble form of the murine LIF-R and has no transmembrane region. The absence of the transmembrane region allows the protein molecule to be transported through the cell membrane. The coding region spans from nucleotides 53-2212. The amino acid sequence of the mature peptide encoded by this nucleotide sequence is defined by amino acids 1-676. The predicted signal peptide is defined by amino acids - 43 through -1. Proteins and Analogs The present invention provides isolated recombinant mammalian LIF-R polypeptides. Isolated LIF-R polypeptides of this invention are substantially free of other contaminating materials of natural or endogenous origin and contain less than about 1% by mass of protein contaminants residual of production processes. The LIF- R polypeptides of this invention are optionally without associated native-pattern glycosylation. Mammalian LIF-R of the present invention includes, by way of example, primate, human, murine, canine, feline, bovine, ovine, equine, caprine and porcine LIF-R. Mammalian LIF-R can be obtained by cross species hybridization, for example using a single stranded cDNA derived from the human LIF-R DNA sequence, clone 65, as a hybridization probe to isolate LIF-R cDNAs from mammalian cDNA libraries. Derivatives of LIF-R within the scope of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and carboxyl groups, for example, a LIF-R protein may be in the form of acidic or basic salts, or may be in neutral form. Individual amino acid residues may also be modified by oxidation or reduction. The primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants. Covalent derivatives are prepared by linking particular functional groups to LIF-R amino acid side chains or at the N- or C-termini. Other derivatives of LIF-R within the scope of this invention include covalent or aggregative conjugates of LIF-R or its fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as N-terminal or C-terminal fusions. For example, the conjugated peptide may be a a signal (or leader) polypeptide sequence at the N-terminal region of the protein which cc-translationally or post-translationally directs transfer of the protein from its site of synthesis to its site of function inside or outside of the cell membrane or wall (e.g., the yeast α-factor leader). LIF-R protein fusions can comprise peptides added to facilitate purification or identification of LIF-R (e.g., poly-His). The amino acid sequence of LIF-R can also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp- Lys (DYKDDDDK) (Hopp et al., Bio/Technology 6: 1204,1988.) The latter sequence is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein. This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in E. coli. LIF-R derivatives may also be used as immunogens, reagents in receptor-based immunoassays, or as binding agents for affinity purification procedures of LIF or other binding ligands. LIF-R derivatives may also be obtained by cross-linking agents, such as M-maleimidobenzoyl succinimide ester and N-hydroxysuccinimide, at cysteine and lysine residues. LIF-R proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromide-activated, bisoxirane-activated, carbonyldϋmidazole-activated or tosyl-activated agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross-linking). Once bound to a substrate, LIF-R may be used to selectively bind (for purposes of assay or purification) anti-LIF-R antibodies or LIF. The present invention also includes LIF-R with or without associated native- pattern glycosylation. LIF-R expressed in yeast or mammalian expression systems, e.g., COS-7 cells, may be similar or slightly different in molecular weight and glycosylation pattern than the native molecules, depending upon the expression system. Expression of LIF-R DNAs in bacteria such as E. coli provides non-glycosylated molecules. Functional mutant analogs of mammalian LIF-R having inactivated N- glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site- specific mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced-carbohydrate form in good yield using yeast expression systems. N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-Ai-Z, where Al is any amino acid except Pro, and Z is Ser or Thr. In this sequence, asparagine provides a side chain amino group for covalent attachment of carbohydrate. Such sites can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between Al and Z, or an amino acid other than Asn between Asn and A i . LIF-R derivatives may also be obtained by mutations of LIF-R or its subunits. A LIF-R mutant, as referred to herein, is a polypeptide homologous to LIF-R but which has an amino acid sequence different from native LIF-R because of a deletion, insertion or substitution. Bioequivalent analogs of LIF-R proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity. For example, cysteine residues can be deleted or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. Generally, substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physic-chemical characteristics resembling those of the residue to be replaced. Similarly, when a deletion or insertion strategy is adopted, the potential effect of the deletion or insertion on biological activity should be considered. Substantially similar polypeptide sequences, as defined above, generally comprise a like number of amino acids sequences, although C-terminal truncations for the purpose of constructing soluble LIF-Rs will contain fewer amino acid sequences. In order to preserve the biological activity of LIF-Rs, deletions and substitutions will preferably result in homologous or conservatively substituted sequences, meaning that a given residue is replaced by a biologically similar residue. Examples of conservative substitutions include substitution of one aliphatic residue for another, such as lie, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; GIu and Asp; or Gin and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are well known. Moreover, particular amino acid differences between human, murine and other mammalian LIF-Rs is suggestive of additional conservative substitutions that may be made without altering the essential biological characteristics of LIF-R. Subunits of LIF-R may be constructed by deleting terminal or internal residues or sequences. Particularly preferred sequences include those in which the transmembrane region and intracellular domain of LIF-R are deleted or substituted with hydrophilic residues to facilitate secretion of the receptor into the cell culture medium. Soluble LIF-R proteins may also include part of the transmembrane region, provided that the soluble LIF-R protein is capable of being secreted from the cell. The resulting protein is referred to as a soluble LIF-R molecule which retains its ability to bind LIF. The present invention contemplates such soluble LIF-R constructs corresponding to all or part of the extracellular region of LIF-R. The resulting soluble LIF-R constructs are then inserted and expressed in appropriate expression vectors and assayed for the ability to bind LIF, as described in Example 1. Biologically active soluble LIF-Rs resulting from such constructions are also contemplated to be within the scope of the present invention. Mutations in nucleotide sequences constructed for expression of analog LIF-R must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures such as loops or hairpins which would adversely affect translation of the receptor mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation per se be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed LIF-R mutants screened for the desired activity. Not all mutations in the nucleotide sequence which encodes LIF-R will be expressed in the final product, for example, nucleotide substitutions may be made to enhance expression, primarily to avoid secondary structure loops in the transcribed mRNA (see EPA 75.444A, incorporated herein by reference), or to provide codons that are more readily translated by the selected host, e.g., the well-known E. coli preference codons for E. coli expression. Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Patent Nos. 4,518,584 and 4,737,462 disclose suitable techniques, and are incorporated by reference herein. Both monovalent forms and polyvalent forms of LIF-R are useful in the compositions and methods of this invention. Polyvalent forms possess multiple LIF-R binding sites for LIF ligand. For example, a bivalent soluble LIF-R may consist of two tandem repeats of the extracellular region of LIF-R, separated by a linker region. Alternate polyvalent forms may also be constructed, for example, by chemically coupling LIF-R to any clinically acceptable carrier molecule, a polymer selected from the group consisting of Ficoll, polyethylene glycol or dextran using conventional coupling techniques. Alternatively, LIF-R may be chemically coupled to biotin, and the biotin-LIF-R conjugate then allowed to bind to avidin, resulting in tetravalent avidin/biotin/LIF-R molecules. LIF-R may also be covalentiy coupled to dinitrophenol (DNP) or trinirrophenol (TNP) and the resulting conjugate precipitated with anti-DNP or anti-TNP-IgM, to form decameric conjugates with a valency of 10 for LIF-R binding sites. A recombinant chimeric antibody molecule may also be produced having LIF-R sequences substituted for the variable domains of either or both of the immunoglobulin molecule heavy and light chains and having unmodified constant region domains. For example, chimeric LIF-R/IgGi a y be produced from two chimeric genes — a LIF- R human k light chain chimera (LIF-R/C k ) and a LIF-R/human gl heavy chain chimera (LIF-R/Cg-i). Following transcription and translation of the two chimeric genes, the gene products assemble into a single chimeric antibody molecule having LIF-R displayed bivalently. Such polyvalent forms of LIF-R may have enhanced binding affinity for LIF ligand. Additional details relating to the construction of such chimeric antibody molecules are disclosed in WO 89/09622 and EP 315062. Expression of Recombinant LIF-R The present invention provides recombinant expression vectors to amplify or express DNA encoding LIF-R. Recombinant expression vectors are replicable DNA constructs which have synthetic or cDNA-derived DNA fragments encoding mammalian LIF-R or bioequivalent analogs operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes. A transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences, as described in detail below. Such regulatory elements may include an operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated. DNA regions are operably linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame. Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product. DNA sequences encoding mammalian LIF-Rs which are to be expressed in a microorganism will preferably contain no introns that could prematurely terminate transcription of DNA into mRNA; however, premature termination of transcription may be desirable, for example, where it would result in mutants having advantageous C- terminal truncations, for example, deletion of a transmembrane region to yield a soluble receptor not bound to the cell membrane. Due to code degeneracy, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. Other embodiments include sequences capable of hybridizing to clone 65 under moderately stringent conditions (50"C, 2x SSC) and other sequences hybridizing or degenerate to those which encode biologically active LIF-R polypeptides. Recombinant LIF-R DNA is expressed or amplified in a recombinant expression system comprising a substantially homogeneous monoculture of suitable host microorganisms, for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated (by transformation or transfection) a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed. Transformed host cells are cells which have been transformed or transfected with LIF-R vectors constructed using recombinant DNA techniques. Transformed host cells ordinarily express LIF-R, but host cells transformed for purposes of cloning or amplifying LIF-R DNA do not need to express LIF-R. Expressed LIF-R will be deposited in the cell membrane or secreted into the culture supernatant, depending on the LIF-R DNA selected. Suitable host cells for expression of mammalian LIF-R include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example E. coli or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could also be employed to produce mammalian LIF-R using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. (Cloning Vectors: A Laboratory Manual, Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference. Prokaryotic expression hosts may be used for expression of LIF-R that do not require extensive proteolytic and disulfide processing. Prokaryotic expression vectors generally comprise one or more phenotypic selectable markers, for example a gene encoding proteins conferring antibiotic resistance or supplying an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium, and various species within the genera Pseudomonas, Streptomyces, and Staphyolococcus, although others may also be employed as a matter of choice. Useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 and pGEX (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEMl (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. E. coli is typically transformed using derivatives of pBR322, a plasmid derived from an E. coli species (Bolivar et al., Gene 2:95, 1977). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. Promoters commonly used in recombinant microbial expression vectors include the b-lactamase (penicillinase) and lactose promoter system (Chang et al., Nature 275:615, 1978; and Goeddel et al., Nature 281:544, 1979), the tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res.8:4057, 1980; and EPA 36,776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p.412, 1982). A particularly useful bacterial expression system employs the phage 1 PL promoter and cI857ts thermolabile repressor. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the 1 P promoter include plasmid pHUB2, resident in E. coli strain JMB9 (ATCC 37092) and pPLc28, resident in E. coli RR1 (ATCC 53082). Recombinant LIF-R proteins may also be expressed in yeast hosts, preferably from the Saccharomyces species, such as S. cerevisiae. Yeast of other genera, such as Pichia or Kluyveromyces may also be employed. Yeast vectors will generally contain an origin of replication from the 2m yeast plasmid or an autonomously replicating sequence (ARS), promoter, DNA encoding LIF-R, sequences for polyadenylation and transcription termination and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and E. coli, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 or URA3 gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream. The presence of the TRP1 or URA3 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan or uracil. Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., /. Biol. Chem.255:2073, 1980) or other glycolytic enzymes (Hess et aL, /. Adv. Enzyme Reg. 7:149, 1968; and Holland et al., Biochem. 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6- phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., EPA 73,657. Preferred yeast vectors can be assembled using DNA sequences from pUC18 for selection and replication in E. coli (Amp 1" gene and origin of replication) and yeast DNA sequences including a glucose-repressible ADH2 promoter and α-factor secretion leader. The ADH2 promoter has been described by Russell et al. (J. Biol. Chem. 255:2674, 1982) and Beier et al. (Nature 300:724, 1982). The yeast α-factor leader, which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed. See, e.g., Kurjan et al., Cell 30:933, 1982; and Bitter et al., Proc. Natl. Acad. Sci. USA 81:5330, 1984. The leader sequence may be modified to contain, near its 3' end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes. Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is described by Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929, 1978, selecting for Trp + transformants in a selective medium consisting of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 μg/ml adenine and 20 μg ml uracil or URA+ tranformants in medium consisting of 0.67% YNB, with amino acids and bases as described by Sherman et al., Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986. Host strains transformed by vectors comprising the ADH2 promoter may be grown for expression in a rich medium consisting of 1% yeast extract, 2% peptone, and 1% or 4% glucose supplemented with 80 μg/ml adenine and 80 μg/ml uracil. Derepression of the ADH2 promoter occurs upon exhaustion of medium glucose. Crude yeast supernatants are harvested by filtration and held at 4 * C prior to further purification. Various mammalian or insect cell culture systems are also advantageously employed to express recombinant protein. Expression of recombinant proteins in mammalian cells is particularly preferred because such proteins are generally correctly folded, appropriately modified and completely functional. Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (Cell 23:175, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell lines. Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:41 (1988). The transcriptional andtranslational control sequences in expression vectors to be used in transforming vertebrate cells may be provided by viral sources. For example, commonly used promoters and enhancers are derived fromPolyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, S V40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence. The early and late promoters are particularly useful because both are obtained easily from the virus as a fragment which also contains the S V40 viral origin of rephcation (Fiers et al., Nature 273:113, 1978). Smaller or larger S V40 fragments may also be used, provided the approximately 250 bp sequence extending from the Hind 3 site toward the Bgll site located in the viral origin of replication is included. Further, mammalian genomic LIF- R promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Additional details regarding the use of a mammalian high expression vector to produce a recombinant mammalian LIF-R are provided in Examples 2 below. Exemplary vectors can be constructed as disclosed by Okayama and Berg (Mol. Cell. Biol. 3:280, 1983). A useful system for stable high level expression of mammalian receptor cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (Mol. Immunol. 23:935, 1986). In preferred aspects of the present invention, recombinant expression vectors comprising LIF-R cDNAs are stably integrated into a host cell's DNA. Elevated levels of expression product is achieved by selecting for cell lines having amplified numbers of vector DNA. Cell lines having amplified numbers of vector DNA are selected, for example, by transforming a host cell with a vector comprising a DNA sequence which encodes an enzyme which is inhibited by a known drug. The vector may also comprise a DNA sequence which encodes a desired protein. Alternatively, the host cell may be co-transformed with a second vector which comprises the DNA sequence which encodes the desired protein. The transformed or co-transformed host cells are then cultured in increasing concentrations of the known drug, thereby selecting for drug- resistant cells. Such drug-resistaήt cells survive in increased concentrations of the toxic drug by over-production of the enzyme which is inhibited by the drug, frequently as a result of amplification of the gene encoding the enzyme. Where drug resistance is caused by an increase in the copy number of the vector DNA encoding the inhibitable enzyme, there is a concomitant co-amplification of the vector DNA encoding the desired protein (e.g., LIF-R) in the host cell's DNA. A preferred system for such co-amplification uses the gene for dihydrofolate reductase (DHFR), which can be inhibited by the drug methotrexate (MTX). To achieve co-amplification, a host cell which lacks an active gene encoding DHFR is either transformed with a vector which comprises DNA sequence encoding DHFR and a desired protein, or is co-transformed with a vector comprising a DNA sequence encoding DHFR and a vector comprising a DNA sequence encoding the desired protein. The transformed or co-transformed host cells are cultured in media containing increasing levels of MTX, and those cells lines which survive are selected. A particularly preferred co-amplification system uses the gene for glutamine synthetase (GS), which is responsible for the synthesis of glutamine from glutamate and ammonia using the hydrolysis of ATP to ADP and phosphate to drive the reaction. GS is subject to inhibition by a variety of inhibitors, for example methionine sulphoximine (MSX). Thus, LIF-R can be expressed in high concentrations by co- amplifying cells transformed with a vector comprising the DNA sequence for GS and a desired protein, or co-transformed with a vector comprising a DNA sequence encoding GS and a vector comprising a DNA sequence encoding the desired protein, culturing the host cells in media containing increasing levels of MSX and selecting for surviving cells. The GS co-amplification system, appropriate recombinant expression vectors and cells lines, are described in the following PCT applications: WO 87/04462, WO 89/01036, WO 89/10404 and WO 86/05807. Recombinant proteins are preferably expressed by co-amplification of DHFR or GS in a mammalian host cell, such as Chinese Hamster Ovary (CHO) cells, or alternatively in a murine myeloma cell line, such as SP2/0-Agl4 or NS0 or a rat myeloma cell line, such as YB2/3.0-Ag20, disclosed in PCT applications WO/89/10404 and WO 86/05807. A preferred eukaryotic vector for expression of LIF-R DNA is disclosed below in Example 1. This vector, referred to as pDC303, was derived from the mammalian high expression vector pDC201 and contains regulatory sequences from S V40, CMV and adenovirus. Purification of Recombinant LIF-R Purified mammalian LIF-Rs or analogs are prepared by culturing suitable host vector systems to express the recombinant translation products of the DNAs of the present invention, which are then purified from culture media or cell extracts. For example, supernatants from systems which secrete recombinant soluble LIF-R protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. For example, a suitable affinity matrix can comprise an LIF or lectin or antibody molecule bound to a suitable support. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a LIF-R composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein. Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of recombinant mammalian LIF-R can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Fermentation of yeast which express soluble mammalian LIF-R as a secreted protein greatly simplifies purification. Secreted recombinant protein resulting from a large-scale fermentation can be purified by methods analogous to those disclosed by Urdal et al. (/. Chromatog.296:111, 1984). This reference describes two sequential, reversed-phase HPLC steps for purification of recombinant human GM-CSF on a preparative HPLC column. Human LIF-R synthesized in recombinant culture is characterized by the presence of non-human cell components, including proteins, in amounts and of a character which depend upon the purification steps taken to recover human LIF-R from the culture. These components ordinarily will be of yeast, prokaryotic or non-human higher eukaryotic origin and preferably are present in innocuous contaminant quantities, on the order of less than about 1 percent by weight. Further, recombinant cell culture enables the production of LIF-R free of proteins which may be normally associated with LIF-R as it is found in nature in its species of origin, e.g. in cells, cell exudates or body fluids. Therapeutic Administration of Recombinant Soluble LIF-R The present invention provides methods of using therapeutic compositions comprising an effective amount of soluble LIF-R proteins and a suitable diluent and carrier, and methods for suppressing LIF-dependent biological responses in humans comprising administering an effective amount of soluble LIF-R protein. For therapeutic use, purified soluble LIF-R protein is administered to a patient, preferably a human, for treatment in a manner appropriate to the indication. Thus, for example, soluble LIF-R protein compositions can be administered by bolus injection, continuous infusion, sustained release from implants, or other suitable technique. Typically, a soluble LIF-R therapeutic agent will be administered in the form of a composition comprising purified protein in conjunction with physiologically acceptable carriers, excipients or diluents. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the LIF-R with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with conspecific serum albumin are exemplary appropriate diluents. Preferably, product is formulated as a lyophilizate using appropriate excipient solutions (e.g., sucrose) as diluents. Appropriate dosages can be determined in trials. Because LIF-R proteins bind to LIF, soluble LIF-R proteins can be used to competitively bind to LIF and thereby inhibit binding of LIF to cell surface LIF-R proteins. Soluble LIF-R is therefore expected to inhibit LIF-dependent biological activities. Soluble LIF-R may, for example, be useful in therapy to inhibit the effects of LIF induced cachexia in cancer patients or to treat lipoprotein metabolism defects such as atherosclerosis and obesity. Soluble LIF-R may also be useful in the treatment of disorders of bone and calcium metabolism or disorders associated with LIF overproduction associated with hepatocytes, neurons, and leukocytes. The regulation of embryonic and hematopoietic stem cells by LIF may also be manipulated with soluble LIF-R. Soluble LIF-R may also be used to treat leukemic cells which respond to LIF by proliferating. LIF-R or antibodies to LIF-R may also be useful as a diagnostic reagent to detect diseases characterized by the presence of abnormal LIF-R. The following examples are offered by way of illustration, and not by way of limitation. EXAMPLES Example 1 Isolation and Expression of cDNAs Encoding Human LIF-R A. Radiolabeling of LIF. Recombinant human LIF was expressed in yeast and purified to homogeneity essentially as described by Hopp, et al., Bio/Technology 6:1204, 1988. The purified protein was radiolabeled using a commercially available enzymobead radioiodination reagent (BioRad). In this procedure 10 μg rLIF in 50 μl 0.2 M sodium phosphate, pH 7.2, are combined with 50 μl enzymobead reagent, 2 MCi of sodium iodide in 20 μl of 0.05 M sodium phosphate pH 7.0 and 10 μl of 2.5% b-D-glucose. After 10 min at 25°C, sodium azide (20 μl of 50 mM) and sodium metabisulfite (10 μl of 5 mg/ml) were added and incubation continued for 5 min. at 25°C. The reaction mixture was fractionated by gel filtration on a 2 ml bed volume of Sephadex® G-25 (Sigma) equilibrated in Roswell Park Memorial Institute (RPMI) 1640 medium containing 2.5% (w/v) bovine serum albumin (BSA), 0.2% (w/v) sodium azide and 20 mM Hepes pH 7.4 (binding medium). The final pool of 125 I-LIF was diluted to a working stock solution of 3 x 10 -8 M in binding medium and stored for up to one month at 4°C without detectable loss of receptor binding activity. The specific activity is routinely in the range of 6-8 x 10 15 cpm/mmole LIF. B. Membrane Binding Assays. Human placental membranes were incubated at 4 * C for 2 hr with 125 I-LIF in binding medium, 0.1 % bacitracin, 0.02% aprotinin, and 0.4% BSA in a total volume of 1.2 ml. Control tubes containing in addition a 100-fold molar excess of unlabeled LIF were also included to determine non-specific binding. The reaction mixture was then centrifuged at 15,000x g in a microfuge for 5 minutes. Supernatants were discarded, the surface of the membrane pellets carefully rinsed with ice-cold binding medium, and the radioactivity counted on a gamma counter. Using this assay, it was determined that the LIF-R was present on placental membranes, and up to 96 fmols of 125 I-LIF could be bound per mg of placental membrane protein. C. Construction and Screening of Placental cDNA Library. A tissue source for LIF-R was selected by screening various human cell lines and tissues for expression of LEF-R based on their ability to bind 125 I-labeled LIF, prepared as described above in Example 1 A. An unsized cDNA library was constructed by reverse transcription of polyadenylated mRNA isolated from total RNA extracted from the human placental tissue (Ausubel et al., eds., Current Protocols in Molecular Biology, Vol. 1, 1987). The cells were harvested by lysing the tissue cells in a guanidinium isothiocyanate solution and total RNA was isolated using standard techniques as described by Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982. Polyadenylated RNA was isolated by oligo dT cellulose chromatography and double-stranded cDNA was prepared by a method similar to that of Gubler and Hoffman, Gene 25:263, 1983. Briefly, the polyadenylated RNA was converted to an RNA-cDNA hybrid with reverse transcriptase using oligo dT as a primer. The RNA- cDNA hybrid was then converted into double-stranded cDNA using RNAase H in combination with DNA polymerase I. The resulting double stranded cDNA was blunt- ended with T4 DNA polymerase. BgHL adaptors were ligated to the 5' ends of the resulting blunt-ended cDNA as described by Haymerle, et al., Nucleic Acids Research 14:8615, 1986. The non-ligated adaptors were removed by gel filtration chromatography at 68°C, leaving 24 nucleotide non-self-complementary overhangs on the cDNA. The same procedure was used to convert the 5' Bg Ω. ends of the mammalian expression vector pDC303 (ATCC 68102) to 24 nucleotide overhangs complementary to those added to the cDNA. Optimal proportions of adaptored vector and cDNA were ligated in the presence of T4 polynucleotide kinase. Dialyzed ligation mixtures were electroporated into E. coli strain DH5a and transformants selected on ampicillin plates. The resulting cDNAs were ligated into the eukaryotic expression vector pDC303, which was designed to express cDNA sequences inserted at its multiple cloning site when transfected into mammalian cells. pDC303 was assembled from pDC201 (a derivative of pMLSV, previously described by Cosman et al., Nature 312: 768, 1984), SV40 and cytomegalovirus DNA and comprises, in sequence: (1) SV40 sequences from coordinates 5171-270 containing the origin of replication, enhancer sequences and early and late promoters; (2) cytomegalovirus sequences containing the promoter and enhancer regions (nucleotides 671 to +63 from the sequence published by Boechart et al., Cell 41:521, 1985; (3) adenovirus-2 sequences from coordinates 5779- 6079 containing sequences for the first exon of the tripartite leader (TPL), coordinates 7101-7172 and 9634-9693 containing the second exon and part of the third exon of the TPL and a multiple cloning site (MCS) containing sites for Xhol, Kpnl, Smal andBgll; (4) SV40 sequences from coordinates 4127-4100 and 2770-2533 containing the polyadenylation and termination signals for early transcription; (5) adenovirus sequences from coordinates 10532-11156 of the virus-associated RNA genes VAI and VAϋ; and (6) pBR322 sequences from coordinates 4363-2486 and 1094-375 containing the ampicillin resistance gene and origin of replication. The resulting human placental cDNA library in pDC303 was used to transform E. coli strain DH5α, andrecombinants were plated to provide approximately 2,400 colonies per plate and sufficient plates to provide approximately 240,000 total colonies per screen. Colonies were scraped from each plate, pooled, and plasmid DNA prepared from each pool. The pooled DNA was then used to transfect a sub-confluent layer of monkey COS-7 cells. COS-7 cells were prepared for transfection by being maintained in complete medium (Dulbecco's modified Eagle's media (DMEM) containing 10% (v/v) fetal calf serum (FCS), 50 U/ml penicillin, 50 /ml streptomycin, 2 mM L-glutamine) and then plated at a density of 2 x 10 5 cells/well in either 6 well dishes (Falcon) or single well chambered slides (Lab-Tek). Both dishes and slides were pretreated with 1 ml human fibronectin (10 ug/ml in PBS) for 30 minutes followed by 1 wash with PBS. Media was removed from the adherent cell layer and replaced with 1.5 ml complete medium containing 134 mM chloroquine sulfate. 0.2 mis of DNA solution (2 μg DNA, 0.5 mg ml DEAE-dextran in complete medium containing chloroquine) was then added to the cells and incubated for 5 hours. Following the incubation, the media was removed and the cells shocked by addition of complete medium containing 10% DMSO for 2 1/2 to 20 minutes followed by replacement of the solution with fresh complete medium. The cells were grown in culture to permit transient expression of the inserted sequences. These conditions led to an 80% transfection frequency in surviving COS-7 cells. After 48 to 72 hours, transfected monolayers of COS-7 cells were assayed for expression of LIF binding proteins by binding radioiodinated LIF (prepared as described above) using the following slide autoradiography technique. Transfected COS-7 cells were washed once with binding medium (RPMI media 1640 containing 25 mg/ml bovine serum albumin (BSA), 2 mg ml sodium azide, 20 mM HEPES, pH 7.2, and 50 mg/ml nonfat dry milk (NFDM) and incubated for 2 hours at 4 * C with 1 ml binding medium + NFDM containing 1.25 x 10 ~ 9 M 125 I-LIF. After incubation, cells in the chambered slides were washed three times with binding buffer + NFDM, followed by 2 washes with PBS, pH 7.3, to remove unbound 125 I-LIF. The cells were fixed by incubating for 30 minutes at room temperature in 10% glutaraldehyde in PBS, pH 7.3, washed twice in PBS, and air dried. The slides were dipped in Kodak NTB-2 photographic emulsion (5x dilution in water) and exposed in the dark for 12 hours to 7 days at 4"C in a light proof box. The slides were then developed for approximately 5 minutes in Kodak D 19 developer (40 g 500 ml water), rinsed in water and fixed in Agfa G433C fixer. The slides were individually examined with a microscope at 25-40x magnification and positive cells expressing LIF-R were identified by the presence of autoradiographic silver grains against a light background. Cells in the 6 well plates were washed once with binding buffer + NFDM followed by 3 washings with PBS, pH 7.3, to remove unbound 125 I-LIF. The bound cells were then trypsinized to remove them from the plate and bound 125 I-LIF were counted on a gamma counter. Using the slide autoradiography approach, approximately 240,000 cDNAs were screened in pools of approximately 2,400 cDNAs until assay of one transfectant pool showed multiple cells clearly positive for LIF binding. This pool was then partitioned into pools of 600 and again screened by slide autoradiography and a positive pool was identified. This pool was further partitioned into pools of 60 and screened against by slide autoradiography until a positive pool was identified. Individual colonies from this pool of 60 were screened until a single clone (clone 65) was identified which directed synthesis of a surface protein with detectable LIF binding activity. This clone was isolated, and its insert is sequenced to determine the sequence of the human LIF-R cDNA clone 65. The pDC303 cloning vector containing the human LIF-R cDNA clone 65 was deposited with the American Type Culture Collection, Rockville, MD, USA (ATCC) on December 11 , 1990, under the name pHLIFR-65, and was assigned ATCC Accession Number 68491. D. Binding to Intact Cells. Binding assays done with DA-1 cells grown in suspension culture were performed by a phthalate oil separation method (Dower et al., J. Immunol. 132:751, 1984) essentially as described by Park et al., /. Biol. Chem 267:4177, 1986 and Park et al., Proc. Natl. Acad. Sci. USA 84:5261, 1987. Nonspecific binding of 125 I-LIF was measured in the presence of a 200-fold or greater molar excess of unlabeled LIF. Sodium azide (0.2%) was included in all binding assays to inhibit internalization of 125 I-LIF at 37°C. The DA-1 cells bound 125 I-LIF, and approximately 200 LIF receptors were determined to be present on the surface cells with an affinity constant (K a ) of about 7.4 x 10 8 M -1 . Plasmid DNA from LIF receptor expression plasmid was used to transfect a sub- confluent layer of monkey COS-7 cells using DEAE-dextran followed by chloroquine treatment, as described by Luthman et al. (Nucl Acids Res. 11:1295, 1983) and McCutchan et al. (/. Natl. Cancer Inst.41:351, 1968). The cells were then grown in culture for three days to permit transient expression of the inserted sequences. After three days the cell monolayers were assayed for 125 I-LIF binding essentially as described by Mosley et al., Cell 59:335, 1989. Non-specific binding of 1 5 I-LIF was measured in the presence of 200-fold or greater excess of unlabeled LIF. Initial binding studies of 125 I-LIF to COS cells tranfected with LIF-R cDNA clone 65 indicated that high affinity binding (K a > lxlO 9 M _1 ) was apparent following Scatchard analysis. pDC303 control vector transfected cells indicated that background endogenous LIF receptors are present on COS-7 cells. Control vector transfected cells expressed 130 high-affinity LIF receptors (K a = 4.2 xlO 10 M _1 ) and 2,400 receptors with lower affinity (K a = 7.8 xlO 8 M" 1 ). COS-7 cells were transfected with pDC303 containing LIF-R clone 65, and transfected cells were diluted 1:10 in cells that had been transfected with control pDC303 vector. This strategy was utilized as recombinant receptor expression can often be too great to allow accurate determinations of ligand-receptor affinity. Results of these experiments indicate that both affinity classes of LIF receptors were present following transfection with LIF-R clone 65. Approximately 178 high-affinity sites (K a = 1.4 xlO 11 M" 1 ) and 9800 lower affinity sites (K a = 1.1 xlO 9 M' 1 ) were present on the LIF-R transfectants. E. 35 S-Labelling and Affinity Purification of LIF-R. COS-7 cells transfected with pDC303 or pDC303 containing the human LIF-R cDNA clone 65 were radiolabeled with 35 S-cysteine/methionine. Detergent extracts of radiolabeled cells were prepared as described (Mosley et al., supra). LIF affinity matrices were prepared by coupling recombinant human LIF to cyanogen bromide-activated Sepharose (Pharmacia) or Hydrazide Affigel (Biorad), according to manufacturer's recommendations. A protein of M r approximately 190,000 was detected following affinity purification with either matrix, and SDS-PAGE analysis of LIF-R clone 65 COS-7 cell lysates, but was undetectable in control vector transfectants. The LIF-R clone 65 cDNA predicts a molecular weight of 111,374 and likely a high degree of glycosylation makes up the difference between this size and the observed M r of 190,000. Additionally, since the clone 65 LIF-R does not contain a stop codon in the 3' end of the cDNA, translation terminates 3 amino acids into the expression vector. Thus 401 daltons of the 190,000 LIF-R protein are encoded by these vector sequences. Example 2 Isolation and Purification of cDNA Clones Encoding Murine LIF-R A murine LIF-R cDNA was isolated from a library made from mouse liver cDNA (Stratagene, San Diego, Cat. #935302), by cross-species hybridization with a human LIF-R probe. A double-stranded human LIF-R probe was produced by excising a Bgiπ fragment of the human LIF-R clone 65 and 32 P-labelling the cDNA using random primers (Boehringer-Mannheim). A total of about 5xl0 5 plaques were screened with the human probe in 35% formamide. Murine LIF-R cDNA clone 3 was isolated. This particular clone encoded a soluble version of the LIF receptor. The coding region encodes a LIF-R having about 70% identity at the amino acid level (80% similarity) and about 78% identity at the nucleotide level to the human LIF-R in the region of overlap. Example 3 Preparation of Monoclonal Antibodies to LIF-R Preparations of purified recombinant LIF-R, for example, human LIF-R, or transfected COS cells expressing high levels of LIF-R are employed to generate monoclonal antibodies against LIF-R using conventional techniques, for example, those disclosed in U.S. Patent 4,411,993. Such antibodies are likely to be useful in interfering with LIF binding to LIF-R, for example, in ameliorating toxic or other undesired effects of LIF, or as components of diagnostic or research assays for LIF or soluble LIF-R. To immunize mice, LIF-R immunogen is emulsified in complete Freund's adjuvant and injected in amounts ranging from 10-100 μg subcutaneously into Balb/c mice. Ten to twelve days later, the immunized animals are boosted with additional immunogen emulsified in incomplete Freund's adjuvant and periodically boosted thereafter on a weekly to biweekly immunization schedule. Serum samples are periodically taken by retro-orbital bleeding or tail-tip excision for testing by dot-blot assay (antibody sandwich) or ELIS A (enzyme-linked immunosorbent assay). Other assay procedures are also suitable. Following detection of an appropriate antibody titer, positive animals are given an intravenous injection of antigen in saline. Three to four days later, the animals are sacrificed, splenocytes harvested, and fused to the murine myeloma cell line NS 1. Hybridoma cell lines generated by this procedure are plated in multiple microtiter plates in a HAT selective medium (hypoxanthine, aminopterin, and thymidine) to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids. Hybridoma clones thus generated can be screened by ELISA for reactivity with LIF-R, for example, by adaptations of the techniques disclosed by Engvall et al., Immunochem. 5:871 (1971) and in U.S. Patent 4,703,004. Positive clones are then injected into the peritoneal cavities of syngeneic Balb/c mice to produce ascites containing high concentrations (>1 mg/ml) of anti-LIF-R monoclonal antibody. The resulting monoclonal antibody can be purified by ammonium sulfate precipitation followed by gel exclusion chromatography, and/or affinity chromatography based on binding of antibody to Protein A of Staphylococcus aureus. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Gearing, David P. Beckmann, M. P. (ii) TITLE OF INVENTION: Leukemia Inhibitory Factor Receptors (iii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Immunex Corporation (B) STREET: 51 University Street (C) CITY: Seattle (D) STATE: WA (E) COUNTRY: USA (F) ZIP: 98101 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.24 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Wight, Christopher L. (B) REGISTRATION NUMBER: 31,680 (C) REFERENCE/DOCKET NUMBER: 2606-A (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 206-587-0430 (B) TELEFAX: 206-587-0606 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3182 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (F) TISSUE TYPE: Placenta (vii) IMMEDIATE SOURCE: (B) CLONE: hulifr.65 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 179..3182 (D) OTHER INFORMATION: (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 311..3179 (D) OTHER INFORMATION: (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 179..310 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: AGATCTTGGA ACGAGACGAC CTGCTCTCTC TCCCAGAACG TGTCTCTGCT GCAAGGCACC 60 GGGCCCTTTC GCTCTGCAGA ACTGCACTTG CAAGACCATT ATCAACTCCT AATCCCAGCT 120 CAGAAAGGGA GCCTCTGCGA CTCATTCATC GCCCTCCAGG ACTGACTGCA TTGCACAG 178 ATG ATG GAT. ATT TAC GTA TGT TTG AAA CGA CCA TCC TGG ATG GTG GAC 226 Met Met Asp lie Tyr Val Cys Leu Lys Arg Pro Ser Trp Met Val Asp -44 -40 -35 -30 AAT AAA AGA ATG AGG ACT GCT TCA AAT TTC CAG TGG CTG TTA TCA ACA 274 Asn Lys Arg Met Arg Thr Ala Ser Asn Phe Gin Trp Leu Leu Ser Thr -25 -20 -15 TTT ATT CTT CTA TAT CTA ATG AAT CAA GTA AAT AGC CAG AAA AAG GGG 322 Phe lie Leu Leu Tyr Leu Met Asn Gin Val Asn Ser Gin Lys Lys Gly -10 -5 1 GCT CCT CAT GAT TTG AAG TGT GTA ACT AAC AAT TTG CAA GTG TGG AAC 370 Ala Pro His Asp Leu Lys Cys Val Thr Asn Asn Leu Gin Val Trp Asn 5 10 15 20 TGT TCT TGG AAA GCA CCC TCT GGA ACA GGC CGT GGT ACT GAT TAT GAA 418 Cys Ser Trp Lys Ala Pro Ser Gly Thr Gly Arg Gly Thr Asp Tyr Glu 25 30 35 GTT TGC ATT GAA AAC AGG TCC CGT TCT TGT TAT CAG TTG GAG AAA ACC 466 Val Cys lie Glu Asn Arg Ser Arg Ser Cys Tyr Gin Leu Glu Lys Thr 40 45 50 AGT ATT AAA ATT CCA GCT CTT TCA CAT GGT GAT TAT GAA ATA ACA ATA 514 Ser lie Lys lie Pro Ala Leu Ser His Gly Asp Tyr Glu lie Thr lie 55 60 65 AAT TCT CTA CAT GAT TTT GGA AGT TCT ACA AGT AAA TTC ACA CTA AAT 56 Asn Ser Leu His Asp Phe Gly Ser Ser Thr Ser Lys Phe Thr Leu Asn 70 75 80 GAA CAA AAC GTT TCC TTA ATT CCA GAT ACT CCA GAG ATC TTG AAT TTG 61 Glu Gin Asn Val Ser Leu lie Pro Asp Thr Pro Glu lie Leu Asn Leu 85 90 95 100 TCT GCT GAT TTC TCA ACC TCT ACA TTA TAC CTA AAG TGG AAC GAC AGG 65 Ser Ala Asp Phe Ser Thr Ser Thr Leu Tyr Leu Lys Trp Asn Asp Arg 105 110 115 GGT TCA GTT TTT CCA CAC CGC TCA AAT GTT ATC TGG GAA ATT AAA GTT 70 Gly Ser Val Phe Pro His Arg Ser Asn Val lie Trp Glu lie Lys Val 120 125 130 CTA CGT AAA GAG AGT ATG GAG CTC GTA AAA TTA GTG ACC CAC AAC ACA 75 Leu Arg Lys Glu Ser Met Glu Leu Val Lys Leu Val Thr His Asn Thr 135 140 145 ACT CTG AAT GGC AAA GAT ACA CTT CAT CAC TGG AGT TGG GCC TCA GAT 80 Thr Leu Asn Gly Lys Asp Thr Leu His His Trp Ser Trp Ala Ser Asp 150 155 160 ATG CCC TTG GAA TGT GCC ATT CAT TTT GTG GAA ATT AGA TGC TAC ATT 85 Met Pro Leu Glu Cys Ala lie His Phe Val Glu lie Arg Cys Tyr lie 165 170 175 180 GAC AAT CTT CAT TTT TCT GGT CTC GAA GAG TGG AGT GAC TGG AGC CCT 89 Asp Asn Leu His Phe Ser Gly Leu Glu Glu Trp Ser Asp Trp Ser Pro 185 190 195 GTG AAG AAC ATT TCT TGG ATA CCT GAT TCT CAG ACT AAG GTT TTT CCT 94 Val Lys Asn lie Ser Trp lie Pro Asp Ser Gin Thr Lys Val Phe Pro 200 205 210 CAA GAT AAA GTG ATA CTT GTA GGC TCA GAC ATA ACA TTT TGT TGT GTG 994 Gin Asp Lys Val lie Leu Val Gly Ser Asp lie Thr Phe Cys Cys Val 215 220 225 AGT CAA GAA AAA GTG TTA TCA GCA CTG ATT GGC CAT ACA AAC TGC CCC 1042 Ser Gin Glu Lys Val Leu Ser Ala Leu lie Gly His Thr Asn Cys Pro 230 235 240 TTG ATC CAT CTT GAT GGG GAA AAT GTT GCA ATC AAG ATT CGT AAT ATT 1090 Leu lie His Leu Asp Gly Glu Asn Val Ala lie Lys lie Arg Asn lie 245 250 255 260 TCT GTT TCT GCA AGT AGT GGA ACA AAT GTA GTT TTT ACA ACC GAA GAT 1138 Ser Val Ser Ala Ser Ser Gly Thr Asn Val Val Phe Thr Thr Glu Asp 265 270 275 AAC ATA TTT GGA ACC GTT ATT TTT GCT GGA TAT CCA CCA GAT ACT CCT 118 Asn lie Phe Gly Thr Val lie Phe Ala Gly Tyr Pro Pro Asp Thr Pro 280 285 290 CAA CAA CTG AAT TGT GAG ACA CAT GAT TTA AAA GAA ATT ATA TGT AGT 123 Gin Gin Leu Asn Cys Glu Thr His Asp Leu Lys Glu lie lie Cys Ser 295 300 305 TGG AAT CCA GGA AGG GTG ACA GCG TTG GTG GGC CCA CGT GCT ACA AGC 128 Trp Asn Pro Gly Arg Val Thr Ala Leu Val Gly Pro Arg Ala Thr Ser 310 315 320 TAC ACT TTA GTT GAA AGT TTT TCA GGA AAA TAT GTT AGA CTT AAA AGA 1330 Tyr Thr Leu Val Glu Ser Phe Ser Gly Lys Tyr Val Arg Leu Lys Arg 325 330 335 340 GCT GAA GCA CCT ACA AAC GAA AGC TAT CAA TTA TTA TTT CAA ATG CTT 1378 Ala Glu Ala Pro Thr Asn Glu Ser Tyr Gin Leu Leu Phe Gin Met Leu 345 350 355 CCA AAT CAA GAA ATA TAT AAT TTT ACT TTG AAT GCT CAC AAT CCG CTG 1426 Pro Asn Gin Glu lie Tyr Asn Phe Thr Leu Asn Ala His Asn Pro Leu 360 365 370 GGT CGA TCA CAA TCA ACA ATT TTA GTT AAT ATA ACT GAA AAA GTT TAT 1474 Gly Arg Ser Gin Ser Thr lie Leu Val Asn lie Thr Glu Lys Val Tyr 375 380 385 CCC CAT ACT CCT ACT TCA TTC AAA GTG AAG GAT ATT AAT TCA ACA GCT 1522 Pro His Thr Pro Thr Ser Phe Lys Val Lys Asp lie Asn Ser Thr Ala 390 395 400 GTT AAA CTT TCT TGG CAT TTA CCA GGC AAC TTT GCA AAG ATT AAT TTT 1570 Val Lys Leu Ser Trp His Leu Pro Gly Asn Phe Ala Lys lie Asn Phe 405 410 415 420 TTA TGT GAA ATT GAA ATT AAG AAA TCT AAT TCA GTA CAA GAG CAG CGG 1618 Leu Cys Glu lie Glu lie Lys Lys Ser Asn Ser Val Gin Glu Gin Arg 425 430 435 AAT GTC ACA ATC AAA GGA GTA GAA AAT TCA AGT TAT CTT GTT GCT CTG 1666 Asn Val Thr lie Lys Gly Val Glu Asn Ser Ser Tyr Leu Val Ala Leu 440 445 450 GAC AAG TTA AAT CCA TAC ACT CTA TAT ACT TTT CGG ATT CGT TGT TCT 1714 Asp Lys Leu Asn Pro Tyr Thr Leu Tyr Thr Phe Arg lie Arg Cys Ser 455 460 465 ACT GAA ACT TTC TGG AAA TGG AGC AAA TGG AGC AAT AAA AAA CAA CAT 1762 Thr Glu Thr Phe Trp Lys Trp Ser Lys Trp Ser Asn Lys Lys Gin His 470 475 480 TTA ACA ACA GAA GCC AGT CCT TCA AAG GGG CCT GAT ACT TGG AGA GAG 1810 Leu Thr Thr Glu Ala Ser Pro Ser Lys Gly Pro Asp Thr Trp Arg Glu 485 490 495 500 TGG AGT TCT GAT GGA AAA AAT TTA ATA ATC TAT TGG AAG CCT TTA CCC 1858 Trp Ser Ser Asp Gly Lys Asn Leu lie lie Tyr Trp Lys Pro Leu Pro 505 510 515 ATT AAT GAA GCT AAT GGA AAA ATA CTT TCC TAC AAT GTA TCG TGT TCA 19 lie Asn Glu Ala Asn Gly Lys lie Leu Ser Tyr Asn Val Ser Cys Ser 520 525 530. TCA GAT GAG GAA ACA CAG TCC CTT TCT GAA ATC CCT GAT CCT CAG CAC 19 Ser Asp Glu Glu Thr Gin Ser Leu Ser Glu lie Pro Asp Pro Gin His 535 540 545 AAA GCA GAG ATA CGA CTT GAT AAG AAT GAC TAC ATC ATC AGC GTA GTG 20 Lys Ala Glu lie Arg Leu Asp Lys Asn Asp Tyr lie lie Ser Val Val 550 555 560 GCT AAA AAT TCT GTG GGC TCA TCA CCA CCT TCC AAA ATA GCG AGT ATG 20 Ala Lys Asn Ser Val Gly Ser Ser Pro Pro Ser Lys lie Ala Ser Met 565 570 575 580 GAA ATT CCA AAT GAT GAT CTC AAA ATA GAA CAA GTT GTT GGG ATG GGA 20 Glu lie Pro Asn Asp Asp Leu Lys lie Glu Gin Val Val Gly Met Gly 585 590 595 AAG GGG ATT CTC CTC ACC TGG CAT TAC GAC CCC AAC ATG ACT TGC GAC 21 Lys Gly lie Leu Leu Thr Trp His Tyr Asp Pro Asn Met Thr Cys Asp 600 605 610 TAC GTC ATT AAG TGG TGT AAC TCG TCT CGG TCG GAA CCA TGC CTT ATG 219 Tyr Val lie Lys Trp Cys Asn Ser Ser Arg Ser Glu Pro Cys Leu Met 615 620 625 GAC TGG AGA AAA GTT CCC TCA AAC AGC ACT GAA ACT GTA ATA GAA TCT 224 Asp Trp Arg Lys Val Pro Ser Asn Ser Thr Glu Thr Val lie Glu Ser 630 635 640 GAT GAG TTT CGA CCA GGT ATA AGA TAT AAT TTT TTC CTG TAT GGA TGC 229 Asp Glu Phe Arg Pro Gly lie Arg Tyr Asn Phe Phe Leu Tyr Gly Cys 645 650 655 660 AGA AAT CAA GGA TAT CAA TTA TTA CGC TCC ATG ATT GGA TAT ATA GAA 233 Arg Asn Gin Gly Tyr Gin Leu Leu Arg Ser Met lie Gly Tyr lie Glu 665 670 675 GAA TTG GCT CCC ATT GTT GCA CCA AAT TTT ACT GTT GAG GAT ACT TCT 238 Glu Leu Ala Pro lie Val Ala Pro Asn Phe Thr Val Glu Asp Thr Ser 680 685 690 GCA GAT TCG ATA TTA GTA AAA TGG GAA GAC ATT CCT GTG GAA GAA CTT 243 Ala Asp Ser lie Leu Val Lys Trp Glu Asp lie Pro Val Glu Glu Leu 695 700 705 AGA GGC TTT TTA AGA GGA TAT TTG TTT TAC TTT GGA AAA GGA GAA AGA 248 Arg Gly Phe Leu Arg Gly Tyr Leu Phe Tyr Phe Gly Lys Gly Glu Arg 710 715 720 GAC ACA TCT AAG ATG AGG GTT TTA GAA TCA GGT CGT TCT GAC ATA AAA 253 Asp Thr Ser Lys Met Arg Val Leu Glu Ser Gly Arg Ser Asp lie Lys 725 730 735 740 GTT AAG AAT ATT ACT GAC ATA TCC CAG AAG ACA CTG AGA ATT GCT GAT 257 Val Lys Asn lie Thr Asp lie Ser Gin Lys Thr Leu Arg lie Ala Asp 745 750 755 CTT CAA GGT AAA ACA AGT TAC CAC CTG GTC TTG CGA GCC TAT ACA GAT 262 Leu Gin Gly Lys Thr Ser Tyr His Leu Val Leu Arg Ala Tyr Thr Asp 760 765 770 GGT GGA GTG GGC CCG GAG AAG AGT ATG TAT GTG GTG ACA AAG GAA AAT 267 Gly Gly Val Gly Pro Glu Lys Ser Met Tyr Val Val Thr Lys Glu Asn 775 780 785 TCT GTG GGA TTA ATT ATT GCC ATT CTC ATC CCA GTG GCA GTG GCT GTC 2722 Ser Val Gly Leu lie lie Ala lie Leu lie Pro Val Ala Val Ala Val 790 795 800 ATT GTT GGA GTG GTG ACA AGT ATC CTT TGC TAT CGG AAA CGA GAA TGG 2770 lie Val Gly Val Val Thr Ser lie Leu Cys Tyr Arg Lys Arg Glu Trp 805 810 815 820 ATT AAA GAA ACC TTC TAC CCT GAT ATT CCA AAT CCA GAA AAC TGT AAA 2818 lie Lys Glu Thr Phe Tyr Pro Asp lie Pro Asn Pro Glu Asn Cys Lys 825 830 835 GCA TTA CAG TTT CAA AAG AGT GTC TGT GAG GGA AGC AGT GCT CTT AAA 2866 Ala Leu Gin Phe Gin Lys Ser Val Cys Glu Gly Ser Ser Ala Leu Lys 840 845 850 ACA TTG GAA ATG AAT CCT TGT ACC CCA AAT AAT GTT GAG GTT .CTG GAA 2914 Thr Leu Glu Met Asn Pro Cys Thr Pro Asn Asn Val Glu Val Leu Glu 855 860 865 ACT CGA TCA GCA TTT CCT AAA ATA GAA GAT ACA GAA ATA ATT TCC CCA 2962 Thr Arg Ser Ala Phe Pro Lys lie Glu Asp Thr Glu lie lie Ser Pro 870 875 880 GTA GCT GAG CGT CCT GAA GAT CGC TCT GAT GCA GAG CCT GAA AAC CAT 3010 Val Ala Glu Arg Pro Glu Asp Arg Ser Asp Ala Glu Pro Glu Asn His 885 890 895 900 GTG GTT GTG TCC TAT TGT CCA CCC ATC ATT GAG GAA GAA ATA CCA AAC 3058 Val Val Val Ser Tyr Cys Pro Pro lie lie Glu Glu Glu lie Pro Asn 905 910 915 CCA GCC GCA GAT GAA GCT GGA GGG ACT GCA CAG GTT ATT TAC ATT GAT 3106 Pro Ala Ala Asp Glu Ala Gly Gly Thr Ala Gin Val lie Tyr lie Asp 920 925 930 GTT CAG TCG ATG TAT CAG CCT CAA GCA AAA CCA GAA GAA AAA AAA AAA 3154 Val Gin Ser Met Tyr Gin Pro Gin Ala Lys Pro Glu Glu Lys Lys Lys 935 940 945 AAA AGC AGG TCG TCT CGT TCC AAG ATC T 3182 Lys Ser Arg Ser Ser Arg Ser Lys lie 950 955 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1001 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Met Asp lie Tyr Val Cys Leu Lys Arg Pro Ser Trp Met Val Asp -44 -40 -35 -30 Asn Lys Arg Met Arg Thr Ala Ser Asn Phe Gin Trp Leu Leu Ser Thr -25 -20 -15 Phe lie Leu Leu Tyr Leu Met Asn Gin Val Asn Ser Gin Lys Lys Gly -10 -5 1 Ala Pro His Asp Leu Lys Cys Val Thr Asn Asn Leu Gin Val Trp Asn 5 10 15 20 Cys Ser Trp Lys Ala Pro Ser Gly Thr Gly Arg Gly Thr Asp Tyr Glu 25 30 35 Val Cys lie Glu Asn Arg Ser Arg Ser Cys Tyr Gin Leu Glu Lys Thr 40 45 50 Ser lie Lys lie Pro Ala Leu Ser His Gly Asp Tyr Glu lie Thr lie 55 60 65 Asn Ser Leu His Asp Phe Gly Ser Ser Thr Ser Lys Phe Thr Leu Asn 70 75 80 Glu Gin Asn Val Ser Leu lie Pro Asp Thr Pro Glu lie Leu Asn Leu 85 90 95 100 Ser Ala Asp Phe Ser Thr Ser Thr Leu Tyr Leu Lys Trp Asn Asp Arg 105 110 115 Gly Ser Val Phe Pro His Arg Ser Asn Val lie Trp Glu lie Lys Val 120 125 130 Leu Arg Lys Glu Ser Met Glu Leu Val Lys Leu Val Thr His Asn Thr 135 140 145 Thr Leu Asn Gly Lys Asp Thr Leu His His Trp Ser Trp Ala Ser Asp 150 155 160 Met Pro Leu Glu Cys Ala lie His Phe Val Glu lie Arg Cys Tyr lie 165 170 175 180 Asp Asn Leu His Phe Ser Gly Leu Glu Glu Trp Ser Asp Trp Ser Pro 185 190 195 Val Lys Asn lie Ser Trp lie Pro Asp Ser Gin Thr Lys Val Phe Pro 200 205 210 • Gin Asp Lys Val lie Leu Val Gly Ser Asp lie Thr Phe Cys Cys Val 215 220 225 Ser Gin Glu Lys Val Leu Ser Ala Leu lie Gly His Thr Asn Cys Pro 230 235 240 Leu lie His Leu Asp Gly Glu Asn Val Ala lie Lys lie Arg Asn lie 245 250 255 260 Ser Val Ser Ala Ser Ser Gly Thr Asn Val Val Phe Thr Thr Glu Asp 265 270 275 Asn lie Phe Gly Thr Val lie Phe Ala Gly Tyr Pro Pro Asp Thr Pro 280 285 290 Gin Gin Leu Asn Cys Glu Thr His Asp Leu Lys Glu lie ie Cys Ser 295 300 305 Trp Asn Pro Gly Arg Val Thr Ala Leu Val Gly Pro Arg Ala Thr Ser 310 315 320 Tyr Thr Leu Val Glu Ser Phe Ser Gly Lys Tyr Val Arg Leu Lys Arg 325 330 335 340 Ala Glu Ala Pro Thr Asn Glu Ser Tyr Gin Leu Leu Phe Gin Met Leu 345 350 355 Pro Asn Gin Glu lie Tyr Asn Phe Thr Leu Asn Ala His Asn Pro Leu 360 365 370 Gly Arg Ser Gin Ser Thr lie Leu Val Asn lie Thr Glu Lys Val Tyr 375 380 385 Pro His Thr Pro Thr Ser Phe Lys Val Lys Asp lie Asn Ser Thr Ala 390 395 400 Val Lys Leu Ser Trp His Leu Pro Gly Asn Phe Ala Lys lie Asn Phe 405 410 415 420 Leu Cys Glu lie Glu lie Lys Lys Ser Asn Ser Val Gin Glu Gin Arg 425 430 435 Asn Val Thr lie Lys Gly Val Glu Asn Ser Ser Tyr Leu Val Ala Leu 440 445 450 Asp Lys Leu Asn Pro Tyr Thr Leu Tyr Thr Phe Arg lie Arg Cys Ser 455 460 465 Thr Glu Thr Phe Trp Lys Trp Ser Lys Trp Ser Asn Lys Lys Gin His 470 475 480 Leu Thr Thr Glu Ala Ser Pro Ser Lys Gly Pro Asp Thr Trp Arg Glu 485 490 495 500 Trp Ser Ser Asp Gly Lys Asn Leu lie lie Tyr Trp Lys Pro Leu Pro 505 510 515 lie Asn Glu Ala Asn Gly Lys lie Leu Ser Tyr Asn Val Ser Cys Ser 520 525 530 Ser Asp Glu Glu Thr Gin Ser Leu Ser Glu lie Pro Asp Pro Gin His 535 540 545 Lys Ala Glu lie Arg Leu Asp Lys Asn Asp Tyr lie lie Ser Val Val 550 555 560 Ala Lys Asn Ser Val Gly Ser Ser Pro Pro Ser Lys lie Ala Ser Met 565 570 575 580 Glu lie Pro Asn Asp Asp Leu Lys lie Glu Gin Val Val Gly Met Gly 585 590 595 Lys Gly lie Leu Leu Thr Trp His Tyr Asp Pro Asn Met Thr Cys Asp 600 605 610 Tyr Val lie Lys Trp Cys Asn Ser Ser Arg Ser Glu Pro Cys Leu Met 615 620 625 Asp Trp Arg Lys Val Pro Ser Asn Ser Thr Glu Thr Val lie Glu Ser 630 635 640 Asp Glu Phe Arg Pro Gly lie Arg Tyr Asn Phe Phe Leu Tyr Gly Cys 645 650 655 660 Arg Asn Gin Gly Tyr Gin Leu Leu Arg Ser Met lie Gly Tyr lie Glu 665 670 675 Glu Leu Ala Pro lie Val Ala Pro Asn Phe Thr Val Glu Asp Thr Ser 680 685 690 Ala Asp Ser lie Leu Val Lys Trp Glu Asp lie Pro Val Glu Glu Leu 695 700 705 Arg Gly Phe Leu Arg Gly Tyr Leu Phe Tyr Phe Gly Lys Gly Glu Arg 710 715 720 Asp Thr Ser Lys Met Arg Val Leu Glu Ser Gly Arg Ser Asp lie Lys 725 730 735 740 Val Lys Asn lie Thr Asp lie Ser Gin Lys Thr Leu Arg lie Ala Asp 745 750 755 Leu Gin Gly Lys Thr Ser Tyr His Leu Val Leu Arg Ala Tyr Thr Asp 760 765 770 Gly Gly Val Gly Pro Glu Lys Ser Met Tyr Val Val Thr Lys Glu Asn 775 780 785 Ser Val Gly Leu lie lie Ala lie Leu lie Pro Val Ala Val Ala Val 790 795 800 He Val Gly Val Val Thr Ser He Leu Cys Tyr Arg Lys Arg Glu Trp 805 810 815 820 He Lys Glu Thr Phe Tyr Pro Asp He Pro Asn Pro Glu Asn Cys Lys 825 830 835 Ala Leu Gin Phe Gin Lys Ser Val Cys Glu Gly Ser Ser Ala Leu Lys 840 845 850 Thr Leu Glu Met Asn Pro Cys Thr Pro Asn Asn Val Glu Val Leu Glu 855 860 865 Thr Arg Ser Ala Phe Pro Lys He Glu Asp Thr Glu He He Ser Pro 870 875 880 Val Ala Glu Arg Pro Glu Asp Arg Ser Asp Ala Glu Pro Glu Asn His 885 890 895 900 Val Val Val Ser Tyr Cys Pro Pro He He Glu Glu Glu He Pro Asn 905 910 915 Pro Ala Ala Asp Glu Ala Gly Gly Thr Ala Gin Val He Tyr He Asp 920 925 930 Val Gin Ser Met Tyr Gin Pro Gin Ala Lys Pro Glu Glu Lys Lys Lys 935 940 945 Lys Ser Arg Ser Ser Arg Ser Lys He 950 955 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2498 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (vii) IMMEDIATE SOURCE: ( B) CLONE: mulifr-3 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 53..2212 (D) OTHER INFORMATION: (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 182..2209 (D) OTHER INFORMATION: (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 53..181 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CCCCCTCCGT GGCATTGGCT CCTGCCCAGG GGCTGACTGA ACAGCAAGGA CA ATG 5 Met -43 GCA GCT TAC TCA TGG TGG AGA CAG CCA TCG TGG ATG GTA GAC AAT AAA 10 Ala Ala Tyr Ser Trp Trp Arg Gin Pro Ser Trp Met Val Asp Asn Lys -40 -35 -30 AGA TCG AGG ATG ACT CCA AAC CTG CCA TGG CTC CTG TCA GCT CTG ACC 15 Arg Ser Arg Met Thr Pro Asn Leu Pro Trp Leu Leu Ser Ala Leu Thr -25 -20 -15 CTC CTG CAT CTG ACG ATG CAT GCA AAC GGT CTG AAG AGA GGG GTA CAA 19 Leu Leu His Leu Thr Met His Ala Asn Gly Leu Lys Arg Gly Val Gin -10 -5 1 5 GAC TTG AAA TGC ACA ACC AAC AAC ATG CGA GTG TGG GAC TGC ACG TGG 24 Asp Leu Lys Cys Thr Thr Asn Asn Met Arg Val Trp Asp Cys Thr Trp 10 15 20 CCA GCT CCC CTC GGG GTC AGC CCT GGA ACT GTT AAA GAT ATT TGC ATT 29 Pro Ala Pro Leu Gly Val Ser Pro Gly Thr Val Lys Asp He Cys He 25 30 35 AAA GAC AGG TTC CAT TCT TGT CAC CCA TTA GAG ACA ACA AAC GTT AAA 34 Lys Asp Arg Phe His Ser Cys His Pro Leu Glu Thr Thr Asn Val Lys 40 45 50 ATT CCA GCT CTT TCA CCT GGT GAT CAC GAA GTC ACA ATA AAT TAT CTA 39 He Pro Ala Leu Ser Pro Gly Asp His Glu Val Thr He Asn Tyr Leu 55 60 65 70 AAT GGC TTT CAG AGT AAA TTC ACG TTG AAT GAA AAA GAT GTC TCT TTA 43 Asn Gly Phe Gin Ser Lys Phe Thr Leu Asn Glu Lys Asp Val Ser Leu 75 80 85 ATT CCA GAG ACT CCC GAG ATC CTG GAT TTG TCT GCT GAC TTC TTC ACC 48 He Pro Glu Thr Pro Glu He Leu Asp Leu Ser Ala Asp Phe Phe Thr 90 95 100 TCC TCC TTA CTA CTG AAG TGG AAC GAC AGA GGG TCT GCT CTG CCT CAC 53 Ser Ser Leu Leu Leu Lys Trp Asn Asp Arg Gly Ser Ala Leu Pro His 105 110 115 CCC TCC AAT GCC ACC TGG GAG ATT AAG GTT CTA CAG AAT CCA AGG ACG 58 Pro Ser Asn Ala Thr Trp Glu He Lys Val Leu Gin Asn Pro Arg Thr 120 125 130 GAA CCA GTA GCA CTC GTG TTA CTC AAC ACA ATG CTG AGT GGT AAA GAT 63 Glu Pro Val Ala Leu Val Leu Leu Asn Thr Met Leu Ser Gly Lys Asp 135 140 145 150 ACC GTT CAG CAC TGG AAC TGG ACC TCA GAC CTG CCC TTG CAA TGT GCC 679 Thr Val Gin His Trp Asn Trp Thr Ser Asp Leu Pro Leu Gin Cys Ala 155 160 165 ACT CAC TCG GTG AGC ATT CGA TGG CAC ATT GAC TCG CCT CAT TTC TCC 727 Thr His Ser Val Ser He Arg Trp His He Asp Ser Pro His Phe Ser 170 175 180 GGT TAC AAA GAG TGG AGT GAC TGG AGC CCG CTG AAG AAC ATC TCC TGG 775 Gly Tyr Lys Glu Trp Ser Asp Trp Ser Pro Leu Lys Asn He Ser Trp 185 190 195 ATT CGT AAT ACA GAG ACT AAT GTT TTT CCT CAA GAC AAA GTG GTG CTC 823 He Arg Asn Thr Glu Thr Asn Val Phe Pro Gin Asp Lys Val Val Leu 200 205 210 GCA GGC TCA AAC ATG ACA ATT TGT TGT ATG AGT CCA ACG AAA GTG CTT 871 Ala Gly Ser Asn Met Thr He Cys Cys Met Ser Pro Thr Lys Val Leu 215 220 225 230 TCA GGA CAG ATC GGC AAT ACC CTT CGT CCT CTC ATC CAT CTG TAC GGG 919 Ser Gly Gin He Gly Asn Thr Leu Arg Pro Leu He His Leu Tyr Gly 235 240 245 CAA ACC GTT GCG ATC CAT ATC CTG AAC ATC CCC GTT TCT GAA AAC AGT 967 Gin Thr Val Ala He His He Leu Asn He Pro Val Ser Glu Asn Ser 250 255 260 GGC ACA AAC ATC ATT TTC ATC ACA GAC GAC GAT GTG TAC GGA ACG GTG 1015 Gly Thr Asn He He Phe He Thr Asp Asp Asp Val Tyr Gly Thr Val 265 270 275 GTC TTT GCA GGC TAT CCT CCC GAT GTT CCT CAG AAG CTG AGC TGT GAG 1063 Val Phe Ala Gly Tyr Pro Pro Asp Val Pro Gin Lys Leu Ser Cys Glu 280 285 290 ACA CAT GAC TTA AAA GAG ATT ATA TGT AGC TGG AAT CCA GGA AGG ATA 1111 Thr His Asp Leu Lys Glu He He Cys Ser Trp Asn Pro Gly Arg He 295 300 305 310 ACT GGA CTG GTG GGC CCA CGA AAT ACA GAA TAC ACC CTG TTT GAA AGC 1159 Thr Gly Leu Val Gly Pro Arg Asn Thr Glu Tyr Thr Leu Phe Glu Ser 315 320 325 ATT TCA GGA AAA TCG GCA GTA TTT CAC AGG ATT GAA GGA CTT ACA AAC 1207 He Ser Gly Lys Ser Ala Val Phe His Arg He Glu Gly Leu Thr Asn 330 335 340 GAG ACC TAC CGG TTA GGC GTG CAA ATG CAT CCC GGC CAA GAA ATC CAT 12 Glu Thr Tyr Arg Leu Gly Val Gin Met His Pro Gly Gin Glu He His 345 350 355 AAC TTC ACC CTG ACT GGT CGC AAT CCA CTG GGG CAG GCA CAG TCA GCA 13 Asn Phe Thr Leu Thr Gly Arg Asn Pro Leu Gly Gin Ala Gin Ser Ala 360 365 370 GTG GTC ATC AAT GTG ACT GAG AGA GTT GCT CCT CAT GAT CCG ACT TCG 13 Val Val He Asn Val Thr Glu Arg Val Ala Pro His Asp Pro Thr Ser 375 380 385 390 TTG AAA GTG AAG GAC ATC AAT TCA ACA GTT GTT ACA TTT TCT TGG TAT 13 Leu Lys Val Lys Asp He Asn Ser Thr Val Val Thr Phe Ser Trp Tyr 395 400 405 TTA CCA GGA AAT TTT ACA AAG ATT AAT CTT TTA TGT CAA ATT GAA ATT 14 Leu Pro Gly Asn Phe Thr Lys He Asn Leu Leu Cys Gin He Glu He 410 415 420 TGT AAA GCT AAT TCC AAG AAA GAA GTG AGG AAT GCC ACA ATC AGA GGA 14 Cys Lys Ala Asn Ser Lys Lys Glu Val Arg Asn Ala Thr He Arg Gly 425 430 435 GCC GAG GAT TCA ACT TAC CAT GTT GCT GTA GAC AAA TTA AAT CCA TAC 15 Ala Glu Asp Ser Thr Tyr His Val Ala Val Asp Lys Leu Asn Pro Tyr 440 445 450 ACT GCA TAC ACT TTC CGG GTT CGT TGT TCT TCC AAG ACT TTC TGG AAG 15 Thr Ala Tyr Thr Phe Arg Val Arg Cys Ser Ser Lys Thr Phe Trp Lys 455 460 465 470 TGG AGC AGG TGG AGT GAT GAG AAG CGA CAT CTA ACC ACA GAA GCC ACT 16 Trp Ser Arg Trp Ser Asp Glu Lys Arg His Leu Thr Thr Glu Ala Thr 475 480 485 CCT TCA AAG GGA CCA GAC ACT TGG AGA GAG TGG AGT TCT GAT GGA AAA 16 Pro Ser Lys Gly Pro Asp Thr Trp Arg Glu Trp Ser Ser Asp Gly Lys 490 495 500 AAT CTA ATC GTC TAC TGG AAG CCT TTA CCT ATT AAT GAA GCT AAT GGA 17 Asn Leu He Val Tyr Trp Lys Pro Leu Pro He Asn Glu Ala Asn Gly 505 510 515 AAA ATA CTT TCC TAC AAT GTT TCG TGT TCA TTG AAC GAG GAG ACA CAG 17 Lys He Leu Ser Tyr Asn Val Ser Cys Ser Leu Asn Glu Glu Thr Gin 520 525 530 TCA GTT TTG GAG ATC TTC GAT CCT CAA CAC AGA GCA GAG ATA CAG CTT 18 Ser Val Leu Glu He Phe Asp Pro Gin His Arg Ala Glu He Gin Leu 535 540 545 550 AGT AAA AAT GAC TAC ATC ATC AGT GTG GTG GCA AGA AAT TCT GCT GGC 18 Ser Lys Asn Asp Tyr He He Ser Val Val Ala Arg Asn Ser Ala Gly 555 560 565 TCA TCA CCA CCT TCG AAA ATA GCT AGT ATG GAA ATC CCA AAT GAC GAC 192 Ser Ser Pro Pro Ser Lys He Ala Ser Met Glu He Pro Asn Asp Asp 570 575 580 ATC ACA GTA GAG CAA GCG GTG GGG CTA GGA AAC AGG ATC TTC CTC ACC 197 He Thr Val Glu Gin Ala Val Gly Leu Gly Asn Arg He Phe Leu Thr 585 590 595 TGG CGT CAC GAC CCC AAC ATG ACT TGT GAC TAC GTA ATT AAA TGG TGC 202 Trp Arg His Asp Pro Asn Met Thr Cys Asp Tyr Val He Lys Trp Cys 600 605 610 AAC TCA TCT CGG TCT GAG CCC TGC CTC CTG GAC TGG AGA AAG GTT CCT 2071 Asn Ser Ser Arg Ser Glu Pro Cys Leu Leu Asp Trp Arg Lys Val Pro 615 620 625 630 TCA AAC AGC ACG GAG ACT GTC ATA GAG TCT GAT CAG TTT CAG CCA GGA 2119 Ser Asn Ser Thr Glu Thr Val He Glu Ser Asp Gin Phe Gin Pro Gly 635 640 645 GTA AGA TAC AAC TTT TAC CTC TAT GGG TGC ACT AAC CAG GGA TAC CAA 2167 Val Arg Tyr Asn Phe Tyr Leu Tyr Gly Cys Thr Asn Gin Gly Tyr Gin 650 655 660 CTG TTA CGT TCC ATA ATT GGA TAC GTA GAA GAA CTG GAA GCT TAA 2212 Leu Leu Arg Ser He He Gly Tyr Val Glu Glu Leu Glu Ala . 665 670 675 AAACTTGGAA ATGTATCCAG GCCTAACACC AGAGAGGGGA GTATCCCTGA AGTCTGTTTG 2272 AGCGGTCACT TAAAATATGC GGCACATGGG GGGCTGGAGA GATGGCACCG ACTGCTCTTC 2332 CAGAGGTCCT GAGTTCAATT CCCAGCAACC ACATGGTGAC TCACAACCAT CTGTAATGGG 2392 GTCTGGTGCC CTCTTCTGGT GTGTCTGAAG AGAGCAATGG TGGCATACTC ATATGTATAA 2452 AATAAATAAA TAAATCTTTT TAAAAAACCA AAAAAAAAAA AAAAAA 2498 (2) INFORMATION FOR SEQ ID NO: : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 719 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Ala Ala Tyr Ser Trp Trp Arg Gin Pro Ser Trp Met Val Asp Asn -43 -40 -35 -30 Lys Arg Ser Arg Met Thr Pro Asn Leu Pro Trp Leu Leu Ser Ala Leu -25 -20 -15 Thr Leu Leu His Leu Thr Met His Ala Asn Gly Leu Lys Arg Gly Val -10 -5 1 5 Gin Asp Leu Lys Cys Thr Thr Asn Asn Met Arg Val Trp Asp Cys Thr 10 15 20 Trp Pro Ala Pro Leu Gly Val Ser Pro Gly Thr Val Lys Asp He Cys 25 30 35 He Lys Asp Arg Phe His Ser Cys His Pro Leu Glu Thr Thr Asn Val 40 45 50 Lys He Pro Ala Leu Ser Pro Gly Asp His Glu Val Thr He Asn Tyr 55 60 65 Leu Asn Gly Phe Gin Ser Lys Phe Thr Leu Asn Glu Lys Asp Val Ser 70 75 80 85 Leu He Pro Glu Thr Pro Glu He Leu Asp Leu Ser Ala Asp Phe Phe 90 95 100 Thr Ser Ser Leu Leu Leu Lys Trp Asn Asp Arg Gly Ser Ala Leu Pro 105 110 115 His Pro Ser Asn Ala Thr Trp Glu He Lys Val Leu Gin Asn Pro Arg 120 125 130 Thr Glu Pro Val Ala Leu Val Leu Leu Asn Thr Met Leu Ser Gly Lys 135 140 145 Asp Thr Val Gin His Trp Asn Trp Thr Ser Asp Leu Pro Leu Gin Cys 150 155 160 165 Ala Thr His Ser Val Ser He Arg Trp His He Asp Ser Pro His Phe 170 175 180 Ser Gly Tyr Lys Glu Trp Ser Asp Trp Ser Pro Leu Lys Asn He Ser 185 190 195 Trp He Arg Asn Thr Glu Thr Asn Val Phe Pro Gin Asp Lys Val Val 200 205 210 Leu Ala Gly Ser Asn Met Thr He Cys Cys Met Ser Pro Thr Lys Val 215 220 225 Leu Ser Gly Gin lie Gly Asn Thr Leu Arg Pro Leu He His Leu Tyr 230 235 240 245 Gly Gin Thr Val Ala He His He Leu Asn He Pro Val Ser Glu Asn 250 255 260 Ser Gly Thr Asn He He Phe He Thr Asp Asp Asp Val Tyr Gly Thr 265 270 275 Val Val Phe Ala Gly Tyr Pro Pro Asp Val Pro Gin Lys Leu Ser Cys 280 285 290 Glu Thr His Asp Leu Lys Glu He He Cys Ser Trp Asn Pro Gly Arg 295 300 305 He Thr Gly Leu Val Gly Pro Arg Asn Thr Glu Tyr Thr Leu Phe Glu 310 315 320 325 Ser He Ser Gly Lys Ser Ala Val Phe His Arg He Glu Gly Leu Thr 330 335 340 Asn Glu Thr Tyr Arg Leu Gly Val Gin Met His Pro Gly Gin Glu He 345 350 355 His Asn Phe Thr Leu Thr Gly Arg Asn Pro Leu Gly Gin Ala Gin Ser 360 365 370 Ala Val Val He Asn Val Thr Glu Arg Val Ala Pro His Asp Pro Thr 375 380 385 Ser Leu Lys Val Lys Asp He Asn Ser Thr Val Val Thr Phe Ser Trp 390 395 400 405 Tyr Leu Pro Gly Asn Phe Thr Lys He Asn Leu Leu Cys Gin He Glu 410 415 420 He Cys Lys Ala Asn Ser Lys Lys Glu Val Arg Asn Ala Thr He Arg 425 430 435 Gly Ala Glu Asp Ser Thr Tyr His Val Ala Val Asp Lys Leu. Asn Pro 440 445 450 Tyr Thr Ala Tyr Thr Phe Arg Val Arg Cys Ser Ser Lys Thr Phe Trp 455 460 465 Lys Trp Ser Arg Trp Ser Asp Glu Lys Arg His Leu Thr Thr Glu Ala 470 475 480 485 Thr Pro Ser Lys Gly Pro Asp Thr Trp Arg Glu Trp Ser Ser Asp Gly 490 495 500 Lys Asn Leu He Val Tyr Trp Lys Pro Leu Pro He Asn Glu Ala Asn 505 510 515 Gly Lys He Leu Ser Tyr Asn Val Ser Cys Ser Leu Asn Glu Glu Thr 520 525 530 Gin Ser Val Leu Glu He Phe Asp Pro Gin His Arg Ala Glu He Gin 535 540 545 Leu Ser Lys Asn Asp Tyr He He Ser Val Val Ala Arg Asn Ser Ala 550 555 560 565 Gly Ser Ser Pro Pro Ser Lys He Ala Ser Met Glu He Pro Asn Asp 570 575 580 Asp He Thr Val Glu Gin Ala Val Gly Leu Gly Asn Arg He Phe Leu 585 590 595 Thr Trp Arg His Asp Pro Asn Met Thr Cys Asp Tyr Val He Lys Trp 600 605 610 Cys Asn Ser Ser Arg Ser Glu Pro Cys Leu Leu Asp Trp Arg Lys Val 615 620 625 Pro Ser Asn Ser Thr Glu Thr Val He Glu Ser Asp Gin Phe Gin Pro 630 635 640 645 Gly Val Arg Tyr Asn Phe Tyr Leu Tyr Gly Cys Thr Asn Gin Gly Tyr 650 655 660 Gin Leu Leu Arg Ser He He Gly Tyr Val Glu Glu Leu Glu Ala 665 670 675

Claims: CLAIMS We claim: 1. An isolated DNA sequence encoding a mammalian LIF receptor (LIF-R). 2. An isolated DNA sequence according to claim 1 which encodes a human LIF- R. 3. An isolated DNA sequence according to claim 1, selected from the group consisting of: (a) cDNA clones having a nucleotide sequence derived from the coding region of a native mammalian LIF-R gene and which encode biologically active LIF-R protein; (b) DNA sequences capable of hybridization to the clones of (a) under moderately ' stringent conditions and which encode biologically active LIF-R protein; and (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active LIF-R protein. 4. An isolated DNA sequence according to claim 1 which encodes a soluble LIF-R. 5. An isolated DNA sequence according to claim 1 encoding the LIF-R polypeptide expressed by pHLIFR-65 (ATCC 68491). 6. A recombinant expression vector comprising a DNA sequence according to any one of claims 1-5. 7. A process for preparing a mammalian LIF receptor (LIF-R) or an analog thereof, comprising culturing a suitable host cell containing a vector according to claim 6 under conditions promoting expression of the LIF-R encoded by said DNA sequence. 8. An isolated and purified biologically active mammalian LIF receptor (LIF-R) protein. 9. An isolated and purified LIF-R protein according to claim 8, consisting essentially of human LIF-R. 10. An isolated and purified LIF-R protein according to claim 8, consisting essentially of soluble LIF-R. 11. A composition for regulating LIF-dependent biological responses in a mammal, comprising an effective amount of a mammalian LIF receptor (LIF-R) protein according to claim 8, and a suitable diluent or carrier. 12. An assay method for detection of LIF or LBF-R molecules or the interaction thereof, comprising use of a protein according to claim 8. 13. Antibodies immunoreactive with mammalian LIF receptors.

Inventors: BECKMANN M PATRICIA, GEARING DAVID P, BECKMANN, M., PATRICIA, GEARING, DAVID, P.
Applicants: IMMUNEX CORP, IMMUNEX CORPORATION
Application year: 1991
Main classification: C12P21
IPC codes: A61K38, A61P3, A61P7, A61P9, A61P35, C07K14, C07K16, C12N15, C12P21, G01N33